Please visit our current website: Clinical Trials and Notewothy Treatments For Brain Tumors
You can Subscribe to our RSS FEED:
which delivers brain tumor news and additions
to the website via RSS. (Click HERE for
details on RSS.)
New video added: Metastatic Brain Tumors
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
An Emerging Medical Market Play with Great Opportunity
OncoSynergy has joined forces with the Musella Foundation For Brain Tumor Research & Information, Inc
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Dianhydrogalactitol (Val-083) synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells
FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma
Trump administration unveils four executive orders aimed at lowering drug prices
GBM awareness day: Contact your legislators!
First Recurrent GBM Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
Comparative Epidemiology of Gliosarcoma and Glioblastoma and the Impact of Race on Overall Survival: A Systematic Literature Review
Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors
Musella Foundation awards another brain tumor research grants!
Survival, Costs, and Health Care Resource Use by Line of Therapy in US Medicare Patients With Newly Diagnosed Glioblastoma: A Retrospective Observational Study
Everolimus improves the efficacy of dasatinib in PDGFRa-driven glioma
Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients
Is polio the answer to curing brain tumors?
Early Imaging Marker of Progressing Glioblastoma: A Window of Opportunity
Musella Foundation awards two more brain tumor research grants!
First annual Dragon Derby!
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study
We need your supprt for the Promising Pathway Act
David Zagzag, MD, Ph.D. Recognized as a Professional of the Year for 2020 by Strathmore`s Who`s Who Worldwide
ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP
A Systematic Review of Tumor Treating Fields Therapy for High-Grade Gliomas
Brain Tumor News Blast
Enter your email address to subscribe!
Copyright © 1993 - 2020 Musella Foundation- All Rights Reserved.
Website by LcsProductionDesign.com